Perioperative Management of Carvedilol

Key Recommendations for Chronic Beta Blocker Users

The American Heart Association and American College of Cardiology recommend that patients currently taking carvedilol should continue the medication through the day of surgery and throughout the perioperative period, as abrupt discontinuation can precipitate rebound hypertension, myocardial ischemia, or acute cardiac events 1, 2
The American College of Cardiology recommends continuing carvedilol without interruption in patients already receiving it for established indications, such as heart failure, coronary artery disease, hypertension, and arrhythmias, as the 2024 AHA/ACC guideline explicitly states that beta blockers should be continued through the perioperative period as appropriate based on clinical circumstances 1, 2, 3, 4

The American College of Cardiology recommends never initiating carvedilol on the day of surgery in beta blocker-naïve patients, as this significantly increases postoperative mortality and stroke risk, and instead, initiate carvedilol at least 7 days before elective surgery to permit dose titration and assessment of tolerability 1, 2, 4, 5, 6
Patients who initiated beta blockers <7 days before surgery had higher mortality compared to those who started >31 days earlier, highlighting the importance of timely initiation 1

The American College of Cardiology recommends titrating carvedilol to heart rate and blood pressure targets during the perioperative period rather than using fixed high doses, with a target heart rate of 60-80 beats per minute while maintaining systolic blood pressure >100 mm Hg 4, 5, 6, 7

High cardiac risk patients, such as those with coronary artery disease, heart failure, or multiple cardiac risk factors, derive the greatest benefit from continuing carvedilol perioperatively, as it reduces the risk of cardiac complications 3, 4, 5
The American College of Cardiology recommends that CABG patients receive beta blockers for at least 24 hours before surgery to reduce postoperative atrial fibrillation, and carvedilol should be continued in those already taking it 3
Liver transplant candidates already receiving carvedilol for variceal bleeding prophylaxis should continue the medication, as it should not be started in the immediate perioperative period but maintained if already prescribed 7, 8

The American Heart Association and American College of Cardiology recommend not stopping carvedilol abruptly due to concerns about intraoperative hypotension, as the risks of withdrawal exceed the risks of continuation 1, 2
The American College of Cardiology recommends not withholding the morning dose on the day of surgery in chronic users, and not starting carvedilol in the immediate preoperative period (<7 days) or on the day of surgery in previously untreated patients 1, 2
The American College of Cardiology also recommends not using high fixed doses without titration, as this was the harmful approach in the POISE trial 1, 6

Patients on chronic beta blocker therapy must continue their medication through the day of surgery to prevent severe cardiovascular events, as recommended by the American Heart Association 9, 10, 11
Starting beta blockers on the day of surgery is harmful and increases postoperative mortality, with a study demonstrating that high-dose beta blockers initiated on the day of surgery increased stroke risk and all-cause mortality despite reducing cardiac events 9, 10, 11, 12
If a new indication for beta blockade exists, initiate at least 7 days before surgery to permit dose titration and assessment of tolerability, with the American College of Cardiology recommending initiation of beta blockers at least 7 days before surgery 9, 10
Patients who initiated beta blockers <7 days before surgery had higher mortality risk compared to those who started >31 days earlier, highlighting the importance of early initiation of beta blocker therapy 9, 10

Calcium channel blockers should be continued during non-cardiac surgery, as they have been shown to reduce ischemia and supraventricular tachycardia in the perioperative period, according to the European Society of Cardiology 13, 14
Mandatory continuation in patients with Prinzmetal (vasospastic) angina to prevent coronary spasm, with the European Heart Journal recommending continuation of calcium channel blockers in these patients 13, 14
Heart rate-reducing calcium channel blockers may be considered in patients with contraindications to beta blockers, with the American Heart Association recommending their use in these patients 13, 14, 15
Short-acting dihydropyridines should be avoided perioperatively, as they have been associated with increased perioperative mortality in aortic aneurysm surgery, according to a study published in the European Heart Journal 16